Prolonged midazolam elimination half-life

Br J Clin Pharmacol. 1986 Apr;21(4):425-9. doi: 10.1111/j.1365-2125.1986.tb05217.x.


The pharmacokinetics of a fixed dose of midazolam (0.3 mg kg-1 i.v.) were studied in detail in 115 healthy patients or volunteers and nine were found with a prolonged elimination half-life. A further 102 patients had an abbreviated pharmacokinetic study, of whom five showed a similar abnormality. Defective hepatic metabolism of midazolam may be a factor in the aetiology of what appears to be a true phenomenon, occurring in 6% of over 200 fit subjects given a standard dose of the drug.

MeSH terms

  • Benzodiazepines / administration & dosage
  • Benzodiazepines / blood
  • Benzodiazepines / metabolism*
  • Drug Evaluation
  • Half-Life
  • Humans
  • Kinetics
  • Liver / metabolism
  • Metabolic Clearance Rate
  • Midazolam


  • Benzodiazepines
  • Midazolam